In an early trial presented at ESMO 2026, two once-daily pills — vopimetostat and daraxonrasib — shrank tumors in 82% of patients with a genetic subtype of advanced pancreatic cancer, most on their third line of therapy. What the results mean, the side effects, and the Phase 3 test that comes next.